Helicobacter pylori infection is closely associated with gastric cancer development.
However, follow-up studies after H pylori eradication are still scarce.
Dr Takenaka and colleagues from Japan evaluated the cancer preventive effect of H pylori eradication, with special attention to differences in effect according to histology.
|5 of 288 persistent subjects developed gastric cancer|
|Alimentary Pharmacology & Therapeutics|
The research team assessed patients who underwent H pylori eradication therapy.
The team analyzed 1807 patients, who were followed-up endoscopically for at least 1 year.
The incidence of gastric cancer and factors associated with cancer development were investigated.
The team observed that 6 of 1519 H pylori eradicated subjects developed gastric cancer.
The research team noted that 5 of 288 persistent subjects developed gastric cancer.
In addition, the team found that 4 of the eradicated subjects developed the intestinal type, and 2 the diffuse type.
The research team found that 4 of the persistent subjects developed the intestinal type, and 1 the diffuse type.
Kaplan-Meier analysis indicated a significantly lower incidence in eradicated patients than in persistent patients.
The researchers noted that the incidence of intestinal type was lower than in eradicated patients.
The team could not evaluated the diffuse type because of the low incidence.
Dr Takenaka's team concluded, “H pylori-eradicated patients had a reduced incidence of gastric cancer compared with H pylori-persistent patients.”
“Particularly the intestinal type, suggesting that H pylori is strongly associated with intestinal-type gastric cancer.”